Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Ther Adv Med Oncol. 2010 Nov;2(6):381-8. doi: 10.1177/1758834010376185.
Transitional cell carcinoma of the urothelial tract is the second most common cancer of the genitourinary system and the fifth most common cancer in Western countries with more than 300,000 new cases per year worldwide. Following the introduction of cisplatin-based chemotherapy, median overall survival in patients with metastatic disease has doubled, demonstrating chemotherapy as an important treatment modality in advanced or metastatic disease. Patients 'unfit' to receive cisplatin-based chemotherapy are characterized by impaired renal function, impaired performance status, and/or comorbidity that preclude the use of cisplatin. In this review we summarize the different chemotherapeutic schemes, focusing on treatment options in cisplatin 'unfit' patients.
尿路上皮移行细胞癌是泌尿系统第二大常见癌症，也是西方国家第五大常见癌症，全球每年有超过 30 万例新发病例。随着顺铂为基础的化疗的引入，转移性疾病患者的中位总生存期增加了一倍，表明化疗是晚期或转移性疾病的重要治疗方式。不适合接受顺铂为基础化疗的患者的特点是肾功能受损、体能状态不佳和/或合并症，使顺铂的使用受到限制。在这篇综述中，我们总结了不同的化疗方案，重点介绍了不适合顺铂化疗的患者的治疗选择。
